Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial
I'm LongbridgeAI, I can summarize articles.Pfizer reported strong immune responses in a Phase 2 trial of its pediatric 25-valent pneumococcal conjugate vaccine (PF-07872412). The four-dose series demonstrated robust protection against all 25 serotypes and showed safety and tolerability comparable to Prevnar 20. The study involved approximately 400 full-term infants, with mild to moderate local reactions observed.
Key points:
- Data from a phase 2 trial of Pfizer's pediatric 25-valent pneumococcal conjugate vaccine PF-07872412 (25vPnC) showed that a four-dose series of the candidate provoked a robust immune response against all 25 serotypes.
- The shot also demonstrated safety and tolerability similar to four doses of Prevnar 20 (pneumococcal 20-valent conjugate vaccine).
- The study enrolled ~400 full-term infants with the primary objective comparing the safety of PF-07872412 to Prevnar 20. The four-dose series was given at 2, 4, 6, and 12 through 15 months of age.
- Results showed that local injection site reactions were mild to moderate, with those reactions and systemic events similar between those given PF-07872412 and Prevnar 20.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.